At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 700 enrolled
Drug / intervention
fluoxetine or desipraminedrug
Likely dose
fluoxetine or desipramine 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group
National Institute of General Medical Sciences (NIGMS)·interventional·Posted Dec 14, 2005·Updated Oct 10, 2008
In Brief
A Phase 2 clinical trial evaluating fluoxetine or desipramine for Major Depressive Disorder and 2 related conditions. Completed, enrolled 700 participants across 1 site.
Detailed Summary
Our goal is to study pharmacogenetics in Mexican-Americans, using depression treatments as a proof of the concept that pharmacogenetic approaches can be used to optimize treatment strategies for common and complex disorders in this population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 1999
First PostedDec 2005
Primary CompletionMay 2006
Study CompletionOct 2008
TodayJul 2026
First PostedDec 14, 2005
Enrollment StartNov 1, 1999
Primary CompletionMay 1, 2006
Study CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 20.6 years ago
Interventions
fluoxetine or desipraminedrug
fluoxetine 5-40 mg/day desipramine 50-150 mg/day